This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cancer				
Cancer	HER2 (EGFR2; ERBB2; neu); signal transducer and activator of transcription 3 (STAT3)	<p>Mouse studies suggest delivering STAT3 inhibitor-loaded nanoparticles to the tumor microenvironment could boost the efficacy of HER2 cancer vaccines. In a mouse model of <i>Her2</i>-positive mammary cancer, a HER2 vaccine plus a tumor-targeted nanoparticle loaded with a STAT3 inhibitor protected against tumor recurrence, whereas either treatment alone did not. Next steps include evaluating nanoparticle-mediated delivery of multiple therapeutics and testing the loaded nanoparticles in mice with human tumors.</p> <p><i>SciBX</i> 4(30); doi:10.1038/scibx.2011.850 Published online Aug. 4, 2011</p>	Unpatented; unavailable for licensing	<p>Liao, D. <i>et al. Cancer Res.</i>; published online July 22, 2011; doi:10.1158/0008-5472.CAN-11-1264 Contact: Ralph A. Reisfeld, The Scripps Research Institute, La Jolla, Calif. e-mail: reisfeld@scripps.edu</p>